Department of Respiratory Medicine and Allergology, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
Division of Biostatistics, Clinical Research Center, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
Tumori. 2021 Oct;107(5):385-391. doi: 10.1177/0300891620966647. Epub 2020 Oct 20.
Increased serum procalcitonin (PCT), a well-known biomarker for sepsis, has been reported in several cancer types. We aimed to investigate the prognostic impact of PCT in non-small cell lung cancer (NSCLC).
Medical records of 51 consecutive patients with NSCLC (Aichi Medical University Hospital) admitted between July 2017 and July 2018 were retrospectively reviewed. The patients were divided into PCT-low (PCT < 0.1 ng/mL) and PCT-high (PCT ⩾ 0.1 ng/mL) groups, and their clinical characteristics and survival were compared.
In contrast to the PCT-low group (n = 24), the PCT-high group (n = 27) showed significantly worse Performance Status (PS) and overall survival (OS) (PS 0-2/3-4, 16/8 versus 12/15, = 0.034; median OS, not reached versus 127 days, < 0.001), irrespective of the presence of infection ( = 0.785). Multivariate analysis showed that the disease stage (IV versus I-III) and high PCT level (⩾0.1 versus <0.1 ng/mL) were significantly worse prognostic factors with hazard ratios of 3.706 ( = 0.023) and 3.951 ( = 0.010), respectively.
The results suggest that serum PCT in NSCLC was elevated regardless of the presence of infection. Higher PCT levels are associated with poor PS and shorter OS in NSCLC.
降钙素原（PCT）是一种众所周知的脓毒症生物标志物，已在多种癌症类型中得到报道。我们旨在研究 PCT 在非小细胞肺癌（NSCLC）中的预后影响。
回顾性分析了 2017 年 7 月至 2018 年 7 月期间在爱知医科大学医院连续收治的 51 例 NSCLC 患者的病历。将患者分为 PCT-低（PCT<0.1ng/mL）和 PCT-高（PCT ⩾0.1ng/mL）组，比较两组的临床特征和生存情况。
与 PCT-低组（n=24）相比，PCT-高组（n=27）的表现状态（PS）和总生存期（OS）明显更差（PS 0-2/3-4，16/8 与 12/15， =0.034；中位 OS，未达到与 127 天， <0.001），无论是否存在感染（ =0.785）。多因素分析表明，疾病分期（IV 期与 I-III 期）和高 PCT 水平（ ⩾0.1ng/mL 与 <0.1ng/mL）是显著的预后不良因素，风险比分别为 3.706（ =0.023）和 3.951（ =0.010）。
结果表明，NSCLC 患者的血清 PCT 水平升高，无论是否存在感染。较高的 PCT 水平与 NSCLC 患者的 PS 差和 OS 短有关。
